Spero Therapeutics (NASDAQ:SPRO) Stock Rating Lowered by Wall Street Zen

Spero Therapeutics (NASDAQ:SPRO) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Other equities analysts have also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Spero Therapeutics in a research report on Wednesday, October 8th. Zacks Research downgraded Spero Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 13th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $5.00.

Spero Therapeutics Trading Down 0.9%

Shares of SPRO stock opened at $2.26 on Friday. The firm has a fifty day simple moving average of $2.31 and a two-hundred day simple moving average of $2.28. Spero Therapeutics has a 12 month low of $0.51 and a 12 month high of $3.22. The firm has a market capitalization of $127.33 million, a PE ratio of -2.86 and a beta of 1.48.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.12. The firm had revenue of $5.44 million for the quarter, compared to analyst estimates of $12.00 million. Spero Therapeutics had a negative net margin of 108.11% and a negative return on equity of 125.91%. On average, equities analysts predict that Spero Therapeutics will post -1.2 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Esther Rajavelu sold 40,270 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $2.37, for a total value of $95,439.90. Following the sale, the insider owned 869,450 shares in the company, valued at approximately $2,060,596.50. This trade represents a 4.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Spero Therapeutics

Large investors have recently added to or reduced their stakes in the company. Invesco Ltd. bought a new stake in Spero Therapeutics in the 2nd quarter worth approximately $43,000. Dimensional Fund Advisors LP bought a new position in Spero Therapeutics during the third quarter valued at approximately $55,000. Assenagon Asset Management S.A. purchased a new position in shares of Spero Therapeutics during the third quarter worth approximately $70,000. Quadrature Capital Ltd purchased a new position in shares of Spero Therapeutics during the second quarter worth approximately $90,000. Finally, Two Sigma Investments LP bought a new stake in shares of Spero Therapeutics in the 3rd quarter worth approximately $93,000. Hedge funds and other institutional investors own 25.60% of the company’s stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.